Azacitidine for Injection 100 mg/vial For Subcutaneous and Intravenous Use Only Single-Dose Vial ...

FDA Recall #D-0165-2021 — Class II — December 14, 2020

Recall #D-0165-2021 Date: December 14, 2020 Classification: Class II Status: Terminated

Product Description

Azacitidine for Injection 100 mg/vial For Subcutaneous and Intravenous Use Only Single-Dose Vial Manufactured by Shilpa Medicare Limited Jadcherla -509301 INDIA Distributed by: Cipla USA, Inc. 10 Independence Blvd, Suite 300 Warren, NJ 07059 NDC 69097-805-40

Reason for Recall

cGMP deviations: Vials may not be sealed correctly affecting sterility.

Recalling Firm

CIPLA — Warren, NJ

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

2151 vials

Distribution

USA Nationwide

Code Information

Lot #: 7S10182A, Ex 9/2021

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated